Anbio Biotechnology (NNNN) Accumulated Expenses (2023 - 2025)

Anbio Biotechnology has reported Accumulated Expenses over the past 3 years, most recently at $87836.0 for Q4 2025.

  • Quarterly results put Accumulated Expenses at $87836.0 for Q4 2025, down 16.33% from a year ago — trailing twelve months through Dec 2025 was $87836.0 (down 16.33% YoY), and the annual figure for FY2025 was $87836.0, down 16.33%.
  • Accumulated Expenses for Q4 2025 was $87836.0 at Anbio Biotechnology, down from $104979.0 in the prior quarter.
  • Over the last five years, Accumulated Expenses for NNNN hit a ceiling of $130967.0 in Q4 2023 and a floor of $87836.0 in Q4 2025.
  • Median Accumulated Expenses over the past 3 years was $104979.0 (2024), compared with a mean of $107927.3.
  • Biggest five-year swings in Accumulated Expenses: dropped 19.84% in 2024 and later dropped 16.33% in 2025.
  • Anbio Biotechnology's Accumulated Expenses stood at $130967.0 in 2023, then fell by 19.84% to $104979.0 in 2024, then decreased by 16.33% to $87836.0 in 2025.
  • The last three reported values for Accumulated Expenses were $87836.0 (Q4 2025), $104979.0 (Q4 2024), and $130967.0 (Q4 2023) per Business Quant data.